Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$124.06M
EBITDA Margin
-944.37%
TTM Avg
-1132.38%
3Y Avg
-1244.49%
5Y Avg
-1244.49%
Market Cap
$126.43M
EBITDA Margin
-27378.57%
TTM Avg
-16324.37%
3Y Avg
-14117.74%
5Y Avg
-9505.20%
Market Cap
$127.21M
EBITDA Margin
-576.63%
TTM Avg
-556.12%
3Y Avg
-556.12%
5Y Avg
-556.12%
Market Cap
$127.29M
EBITDA Margin
-1312.73%
TTM Avg
-1312.73%
3Y Avg
-1312.73%
5Y Avg
-1312.73%
Market Cap
$121.23M
EBITDA Margin
-445.98%
TTM Avg
-559.71%
3Y Avg
-600.34%
5Y Avg
-1391.92%
Market Cap
$120.60M
EBITDA Margin
-1691.15%
TTM Avg
-1668.02%
3Y Avg
-8474.77%
5Y Avg
-5696.48%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $124.82M | N/A | N/A | N/A | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $124.06M | -944.37% | -1132.38% | -1244.49% | -1244.49% |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | -27378.57% | -16324.37% | -14117.74% | -9505.20% |
| Pyxis Oncology, Inc. (PYXS)vs › | $127.21M | -576.63% | -556.12% | -556.12% | -556.12% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.29M | -1312.73% | -1312.73% | -1312.73% | -1312.73% |
| Seer, Inc. (SEER)vs › | $121.23M | -445.98% | -559.71% | -600.34% | -1391.92% |
| Cibus, Inc. (CBUS)vs › | $120.60M | -1691.15% | -1668.02% | -8474.77% | -5696.48% |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | N/A | N/A | N/A | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $119.81M | N/A | N/A | N/A | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $119.15M | -475.96% | -475.96% | -272.89% | -272.89% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
